A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Risperidone; Ziprasidone

Criteria

Inclusion Criteria:

• Hospitalized patients with schizophrenia

• Miminum PANSS score of 60 when randomized

Exclusion Criteria:

• Planned, regular use of antipsyhotics within 1 week of randomization

• Previous treatment with risperidone that resulted in intolerance or lack of response to risperidone